Is Pharvaris B.V. a good investment? Pharvaris B.V. (PHVS) is currently trading at 33.36 USD. Market analysts have a consensus price target of 57.03 USD. This suggests a potential upside from current levels.
Earnings Schedule: Pharvaris B.V. is expected to release its next earnings report on April 1, 2027. The market consensus estimate for Forward EPS is -3.06.
No, it does not currently pay a dividend.
Pharvaris B.V. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be April 1, 2027. The company currently has a trailing EPS of -3.06.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Community Discussion